Patent 11555190 was granted and assigned to Avidity Biosciences on January, 2023 by the United States Patent and Trademark Office.
Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.